Senti Biosciences is trading at $0.20, down 7.59% in live trading, with broader risk-off sentiment a possible factor.
- No fresh company-specific catalyst was identified for the October 22 decline. The latest disclosed shareholder approvals, on October 15, concerned the merger and a possible reverse split.
- Markets retreated as oil rose after reports of tanker damage in the Strait of Hormuz; supplied market context also showed major indexes lower.
- No volume figure was provided.